PAI Pharma, a US-based pharmaceutical manufacturer in oral liquid generic prescription medicines, along with Olympus Partners, has announced the acquisition of Nivagen Pharmaceuticals, a California-based specialty pharmaceutical company with advanced aseptic manufacturing capabilities and a strong pipeline of ready-to-use sterile injectable products.

The acquisition represents PAI Pharma’s strategy to expand domestic pharmaceutical manufacturing, enhance supply chain resilience and accelerate growth in ready-to-use sterile injectables and hospital-focused therapies. These product categories continue to experience persistent shortages across the US healthcare system, highlighting the need for increased domestic production capacity.

Nivagen operates a newly built, state-of-the-art aseptic manufacturing facility in Sacramento, California, designed to support the production of IV bags, vials, prefilled syringes and cartridges. The company brings a pipeline of more than 20 ready-to-use injectable products, complementing PAI Pharma’s existing sterile portfolio of approximately 10 products in development and four currently on the market. The combined pipeline is expected to enhance PAI Pharma’s ability to supply hospitals and health systems with high-quality, domestically manufactured sterile therapies.

“PAI Pharma is a market leader in ready-to-use oral liquid medicines, and that same commitment to quality, reliability and patient-centric design extends naturally into ready-to-use injectables,” said Kurt Orlofski, Chief Executive Officer of PAI Pharma.

Griffin Barstis, Partner at Olympus Partners, said the acquisition reinforces Olympus’ support for PAI Pharma’s growth strategy. 

He added, “The combination of PAI Pharma’s leadership in oral liquid formulations and Nivagen’s injectable platform creates a differentiated business that is well-positioned to serve hospitals and healthcare providers with critical, high-quality medicines.” 

The transaction aligns with growing national efforts to reshore pharmaceutical manufacturing, reduce dependence on foreign supply chains and ensure consistent access to essential medicines. Ready-to-use sterile injectables remain among the most shortage-prone therapies in the US, underscoring the importance of long-term investment in domestic manufacturing infrastructure, skilled labour and advanced production technologies.

Jay Shukla, President of Nivagen Pharmaceuticals, stated, “This acquisition represents a meaningful investment in American pharmaceutical manufacturing at a time when domestic capacity, reliability and readiness are more important than ever.”

Congressman Ami Bera highlighted the regional impact of the deal, noting that the investment underscores the expanding role of the Sacramento region in strengthening US pharmaceutical manufacturing capacity. He added that the state-of-the-art facility will help expand access to ready-to-use sterile injectable medicines, support hospital systems and improve patient care.